Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma
Article first published online: 13 NOV 2002
Volume 188, Issue 1, pages 81–96, October 2002
How to Cite
Romero, P., Valmori, D., Pittet, M. J., Zippelius, A., Rimoldi, D., Lévy, F., Dutoit, V., Ayyoub, M., Rubio-Godoy, V., Michielin, O., Guillaume, P., Batard, P., Luescher, I. F., Lejeune, F., Liénard, D., Rufer, N., Dietrich, P.-Y., Speiser, D. E. and Cerottini, J.-C. (2002), Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunological Reviews, 188: 81–96. doi: 10.1034/j.1600-065X.2002.18808.x
- Issue published online: 13 NOV 2002
- Article first published online: 13 NOV 2002
Summary: Some cancer patients mount spontaneous T- and B-cell responses against their tumor cells. Autologous tumor reactive CD8 cytolytic T lymphocyte (CTL) and CD4 T-cell clones as well as antibodies from these patients have been used for the identification of genes encoding the target antigens. This knowledge opened the way for new approaches to the immunotherapy of cancer. In this review, we describe the characterization of the structure-function properties of the melanocyte/melanoma tumor antigen Melan-A/MART-1, the assessment of the T-cell repertoire available against this antigen in healthy individuals, and the analysis of naturally acquired and/or vaccine-induced CTL responses to this antigen in patients with metastatic melanoma.